Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 15, 2011, authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,346.0 pence; lowest price paid was 1,331.0 pence.
- Treasury Holdings (Settled): 480,234,284 shares (8.57% of total issued share capital).
- Treasury Holdings (Including Unsettled): 485,084,284 shares (9.47% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,123,198,684 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,500,000 shares. This transaction increased the proportion of shares held in Treasury to 8.57% of issued capital and 9.47% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total cost of the 1,500,000 share repurchase based on the weighted average price between 1,331.0 and 1,346.0 pence.
- Confirm the impact of the 9.47% treasury holding on total voting rights calculations for major shareholders.
- Check subsequent filings for the settlement status of the 4,850,000 shares noted as "purchased but not yet settled."
- Review the remaining authorization limit for share buybacks following this transaction.